Conference Update | Huiliao Bio Attended the Qingli Summit Forum on Gene and Cell Therapy in China to Discuss Cutting - edge Technologies

On June 9, 2023, Dr. Chen Zhong, Vice President and Head of the Chemical Platform at HuiLiao Bio, was invited to speak at the Qingli Fengyun Forum.

Dr. Chen provided a detailed introduction to the underlying logic and research progress of HuiLiao Bio's unique Cell-Like System (CLS) delivery platform. The CLS delivery technology, developed exclusively by HuiLiao Bio, significantly outperforms traditional LNP carriers in terms of delivery efficiency (achieving orders of magnitude improvement in both small and large animal models), organ targeting, safety, and dosage. Additionally, it can be rapidly iterated and upgraded according to the actual needs of target pipelines, laying a solid technical foundation for advancing product pipelines.

Following the presentation, Dr. Chen participated in a panel discussion titled "Nucleic Acid Drugs on the Rise: The Nucleic Acid Era Starting from mRNA 2.0," engaging with other experts on cutting-edge technologies. Dr. Chen stated, "Centered around the innovative cell-like membrane delivery system, HuiLiao has filed over twenty domestic and PCT patents, establishing an mRNA drug R&D platform with international competitiveness and complete independent intellectual property rights. The company has made forward-looking arrangements in early-stage R&D, and the resulting patent portfolio is expected to break the blockade by leading foreign companies. From its inception, HuiLiao Bio has been committed to becoming a hardcore technology company that makes breakthroughs in the underlying technologies of nucleic acid drugs, addressing the most pressing challenges in China's nucleic acid drug development."

#About the Qingli Fengyun Forum#

The 3rd China Gene and Cell Therapy Qingli Fengyun Forum, guided by the National Center for Biotechnology Innovation, was co-organized by the Medical Engineering Transformation and Health Industry Integration Committee of the Chinese Research Hospital Association, Boteng Bio, BioValley, and BioBAY, with support from the Shanghai University of Technology-SJTU School of Medicine Suzhou Medical-Engineering Cross-Innovation Institute. This annual biopharmaceutical event brought together nearly 2,000 participants to discuss the latest advancements in China's cell and gene immunotherapy field, covering topics such as industrial chain collaboration, T-cell therapy manufacturing processes and clinical applications, emerging cell therapy research, gene editing and therapies, mRNA drug development and production, and oncolytic viruses.

#About HuiLiao Bio#

Suzhou HuiLiao Bio is a high-tech Biotech company specializing in the research and industrialization of nucleic acid drugs. The company has established a comprehensive industrial platform based on internationally unique mRNA underlying technologies, dedicated to developing next-generation vaccines and therapeutic drugs for urgent clinical needs. HuiLiao Bio's business spans mRNA drug R&D and regulatory submissions, clinical trial design, data analysis, and industrialization. Leveraging its proprietary cell-like membrane platform, the company is developing efficient vaccines for infectious diseases, cancer vaccines, cell therapies, and protein replacement therapies. Currently, HuiLiao Bio has built a robust "trinity" nucleic acid drug R&D and production platform, including the innovative nucleic acid delivery carrier CLS (Cell-Like System) development platform, the Genmax nucleic acid drug production platform, and a high-throughput, intelligent mRNA design and synthesis platform.